ArticleJournal of lipid research2026
Circulating lipids, lipoproteins, and the risk of idiopathic pulmonary fibrosis: a cohort study and genetic analysis.
Article in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating lipids and lipoproteins have been implicated in lung health and disease, yet their associations with the risk of developing idiopathic pulmonary fibrosis (IPF) remain poorly characterized. We integrated a prospective cohort study of 479,738 United Kingdom Biobank participants (1,236 incident IPF cases during 10 years of follow-up) with two-sample Mendelian randomization (MR) using the largest available genome-wide association data (5,159 IPF cases and 27,459 controls). Circulating lipids and lipoproteins were quantified via NMR spectroscopy (138 biomarkers) and clinical biochemistry (6 biomarkers). Multivariable-adjusted Cox proportional hazards models estimated associations with incident IPF and MR using genetic variants as instruments was performed to assess potential causal relationships. After multiple-testing correction, 83 lipid biomarkers were significantly associated with incident IPF in the prospective analysis. Apolipoprotein B (ApoB)-containing lipoproteins, including LDL and VLDL, showed broadly inverse associations across lipid components and particle sizes. A size-dependent pattern was observed for HDL particles, with small HDL subfractions inversely associated with IPF risk, whereas very large HDL subfractions were positively associated. Inverse associations were also observed for apolipoprotein B, apolipoprotein A1 (ApoA-1), and broader lipid classes, including sphingomyelins. Triangulating evidence across approaches, MR analyses supported inverse associations of genetically predicted total cholesteryl esters and sphingomyelins with IPF risk. This study identifies circulating lipids and lipoproteins associated with IPF risk and highlights cholesterol and sphingolipid metabolism as potential contributors to IPF susceptibility. Further mechanistic studies and validation in independent cohorts are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.